Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas

World News: . []

BERKELEY Calif Nov 09 2018 GLOBE NEWSWIRE -- Aduro Biotech, Inc NASDAQ ADRO today announced presentation of preliminary data from its ongoing Phase 1 dose-finding study of ADU-S100 MIW815 a novel STING stimulator of interferon genes ) pathw...

More news and information about Aduro BioTech, Inc.

Published By:

Globe Newswire: 12:30 GMT Friday 9th November 2018

Published: .

Search for other references to "aduro" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us